Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037149 · ClinicalTrials.gov registry record · Phase 1
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Sirnaomics.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 9
- Study locations
NCT05037149 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Sirnaomics. The registered enrollment target is 50 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT05037149, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Sirnaomics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 9
- Study locations
Study Summary
An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.
Conditions Studied
Interventions
- DRUG STP707
Study Locations (9)
Arizona
- Mayo Clinic - Phoenix
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Yale University - New Haven
Florida
- Mayo Clinic - Jacksonville
Georgia
- Emory University - Atlanta
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Atlantic Health System - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2024-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05037149
The ClinicalTrials.gov registry entry for NCT05037149 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The listed sponsor is Sirnaomics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which STP707 is the first listed.
NCT05037149 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05037149 about?
NCT05037149 is a clinical study titled "Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors". An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.
What is the current status of trial NCT05037149?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-11-01. Estimated completion is 2024-03-30.
What conditions does trial NCT05037149 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05037149?
The interventions under investigation include: STP707 (DRUG).
Who is sponsoring clinical trial NCT05037149?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05037149 being conducted?
This trial has 9 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.